ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced financial results for the quarter and year ended December 31, 2013. For the year ended December 31, 2013, the Company incurred a net loss of $8.8 million, or $0.16 per basic and diluted share, compared to a net loss of $14.5 million for the year ended December 31, 2012, or $0.35 per basic and diluted share. The net loss for 2013 includes a credit of $642,000 related to the revaluation of the Company’s warrant derivatives, and a charge of $724,000 for stock-based compensation. The net loss for 2012 included a charge of $2.3 million related to the revaluation of the warrant derivatives, a $397,000 financing charge and a charge of $496,000 for stock-based compensation. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) shares after opening at $1.29 on last trade day and at the end of the day closed at $1.36. Company price to cash ratio in past twelve months was calculated as 2.56. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) showed a positive weekly performance of 7.94%.
Oncothyreon (NASDAQ:ONTY) was downgraded by Canaccord Genuity from a “buy” rating to a “hold” rating in a research note issued on Friday, Analyst RN reports. They currently have a $4.00 price objective on the stock. Canaccord Genuity’s price target suggests a potential upside of 8.40% from the company’s current price. Oncothyreon Inc (USA) (NASDAQ:ONTY) shares dropped -3.14% in last trading session and ended the day on $3.60. ONTY return on equity ratio is recorded as -37.70% and its return on assets is -34.50%. Oncothyreon Inc (USA) (NASDAQ:ONTY) yearly performance is 63.64%.
Prothena Corp (NASDAQ:PRTA) had its target price raised by RBC Capital from $38.00 to $52.00. The firm currently has an outperform rating on the stock. Prothena Corporation PLC (NASDAQ:PRTA) shares moved up 27.53% in last trading session and was closed at $47.39, while trading in range of $43.76 – $47.49. Prothena Corporation PLC (NASDAQ:PRTA) year to date (YTD) performance is 78.70%.
CEL-SCI Corporation (NYSEMKT:CVM) announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) has activated its first U.S. clinical trial expansion site at 21st Century Oncology in Greenville, North Carolina. The trial is already active in dozens of hospitals and clinical centers in 12 countries. CEL-SCI Corporation (NYSEMKT:CVM) weekly performance is 32.03%. On last trading day company shares ended up $1.69. CEL-SCI Corporation (NYSEMKT:CVM) distance from 50-day simple moving average (SMA50) is 56.47%. Analysts mean target price for the company is $7.00.